Isabelle Ray-Coquard

Summary

Affiliation: Institut Paoli-Calmettes
Country: France

Publications

  1. doi request reprint Final results of ERASME-4: a randomized trial of first-line docetaxel plus either capecitabine or epirubicin for metastatic breast cancer
    Thomas Bachelot
    Département de Cancérologie Médicale et Unité INSERM U590Centre Léon Bérard, 28 rue LaënnecFR 69373 Lyon Cedex 08, France
    Oncology 80:262-8. 2011
  2. doi request reprint A role for maintenance therapy in managing sarcoma
    Isabelle Ray-Coquard
    Département d Oncologie Médicale and EAM Santé Individu Société, Centre Leon Berard, 28 rue Laennec, F 69373 Lyon Cedex 08, France
    Cancer Treat Rev 38:368-78. 2012
  3. pmc A European project on incidence, treatment, and outcome of sarcoma
    Giuseppe Mastrangelo
    Department of Environmental Medicine and Public Health, University of Padua, Padua, Italy
    BMC Public Health 10:188. 2010
  4. pmc Neoadjuvant imatinib in patients with locally advanced non metastatic GIST in the prospective BFR14 trial
    Aurore Blesius
    Department of Medicine, Institut Roussy, Villejuif, France
    BMC Cancer 11:72. 2011
  5. doi request reprint A prospective, observational study describing the haematological response in patients undergoing chemotherapy treated by tri-weekly darbepoetin alfa for anaemia
    I Ray-Coquard
    Centre Leon Berard, 28 rue Laennec, 69008, Lyon, France
    Curr Med Res Opin 26:2653-60. 2010
  6. ncbi request reprint Medical practices and cancer care networks: examples in oncology
    Isabelle Ray-Coquard
    Centre Leon Berard, 28, rue Laennec, 69008 Lyon, France
    Bull Cancer 93:E13-20. 2006
  7. ncbi request reprint [Prognostic factors for febrile neutropenia]
    Isabelle Ray-Coquard
    Centre Leon Berard, 28, rue Laennec, 69008 Lyon, France
    Bull Cancer 93:501-6. 2006
  8. ncbi request reprint [Neoadjuvant chemotherapy and ovarian cancer]
    Isabelle Ray-Coquard
    Centre Leon Berard, Lyon
    Bull Cancer 93:669-76. 2006
  9. ncbi request reprint Sarcomas and malignant phyllodes tumours of the breast--a retrospective study
    C Confavreux
    Centre régional de lutte contre le cancer Léon Bérard, 28 rue Laennec, 69008 Lyon, France
    Eur J Cancer 42:2715-21. 2006
  10. pmc Intensified dose of cyclophosphamide with G-CSF support versus standard dose combined with platinum in first-line treatment of advanced ovarian cancer a randomised study from the GINECO group
    I Ray-Coquard
    Centre Leon Berard, EA 4129 sis, 28 rue Laennec, Lyon 69008, France
    Br J Cancer 97:1200-5. 2007

Detail Information

Publications87

  1. doi request reprint Final results of ERASME-4: a randomized trial of first-line docetaxel plus either capecitabine or epirubicin for metastatic breast cancer
    Thomas Bachelot
    Département de Cancérologie Médicale et Unité INSERM U590Centre Léon Bérard, 28 rue LaënnecFR 69373 Lyon Cedex 08, France
    Oncology 80:262-8. 2011
    ..To assess the efficacy of capecitabine plus docetaxel (XT) versus epirubicin plus docetaxel (ET) as first-line therapy for metastatic breast cancer (MBC)...
  2. doi request reprint A role for maintenance therapy in managing sarcoma
    Isabelle Ray-Coquard
    Département d Oncologie Médicale and EAM Santé Individu Société, Centre Leon Berard, 28 rue Laennec, F 69373 Lyon Cedex 08, France
    Cancer Treat Rev 38:368-78. 2012
    ..One such mTOR inhibitor, ridaforolimus (AP23573, MK-8669), is currently being evaluated in patients with advanced bone and STS in the ongoing Sarcoma mUlti-Center Clinical Evaluation of the Efficacy of riDaforolimus (SUCCEED) trial...
  3. pmc A European project on incidence, treatment, and outcome of sarcoma
    Giuseppe Mastrangelo
    Department of Environmental Medicine and Public Health, University of Padua, Padua, Italy
    BMC Public Health 10:188. 2010
    ....
  4. pmc Neoadjuvant imatinib in patients with locally advanced non metastatic GIST in the prospective BFR14 trial
    Aurore Blesius
    Department of Medicine, Institut Roussy, Villejuif, France
    BMC Cancer 11:72. 2011
    ..We analyzed the outcome of patients with non metastatic locally advanced primary GIST treated with IM within the prospective BFR14 phase III trial...
  5. doi request reprint A prospective, observational study describing the haematological response in patients undergoing chemotherapy treated by tri-weekly darbepoetin alfa for anaemia
    I Ray-Coquard
    Centre Leon Berard, 28 rue Laennec, 69008, Lyon, France
    Curr Med Res Opin 26:2653-60. 2010
    ..Response was also assessed according to baseline characteristics including iron, folate and vitamin B12 status...
  6. ncbi request reprint Medical practices and cancer care networks: examples in oncology
    Isabelle Ray-Coquard
    Centre Leon Berard, 28, rue Laennec, 69008 Lyon, France
    Bull Cancer 93:E13-20. 2006
    ..This article provides a state-of-the-art overview of the subject, notably in the domain of oncology where substantial advances are being made...
  7. ncbi request reprint [Prognostic factors for febrile neutropenia]
    Isabelle Ray-Coquard
    Centre Leon Berard, 28, rue Laennec, 69008 Lyon, France
    Bull Cancer 93:501-6. 2006
    ..Research in quantifying the risk of neutropenic complications may make it possible in the near future to target patients at greater risk with appropriate preventive strategies, thereby maximizing the benefits and minimizing the costs...
  8. ncbi request reprint [Neoadjuvant chemotherapy and ovarian cancer]
    Isabelle Ray-Coquard
    Centre Leon Berard, Lyon
    Bull Cancer 93:669-76. 2006
    ..The strategy of neoadjuvant chemotherapy, followed by interval debulking surgery, should be confirmed in a prospective randomized trial. The EORTC55971 trial is currently addressing this issue...
  9. ncbi request reprint Sarcomas and malignant phyllodes tumours of the breast--a retrospective study
    C Confavreux
    Centre régional de lutte contre le cancer Léon Bérard, 28 rue Laennec, 69008 Lyon, France
    Eur J Cancer 42:2715-21. 2006
    ..They are composed of a connective tissue stroma and epithelial elements. Pathological presentation ranges from grade I to malignant phyllodes tumours (grade III) where the stromal component clearly exhibits a sarcoma pattern...
  10. pmc Intensified dose of cyclophosphamide with G-CSF support versus standard dose combined with platinum in first-line treatment of advanced ovarian cancer a randomised study from the GINECO group
    I Ray-Coquard
    Centre Leon Berard, EA 4129 sis, 28 rue Laennec, Lyon 69008, France
    Br J Cancer 97:1200-5. 2007
    ..05). Increasing cyclophosphamide dose by more than 3 times with filgrastim support in the modified CAP regimen CEP induces more toxicity but not better efficacy in AOC...
  11. ncbi request reprint [Are antiangiogenic antibodies universal for solid tumor?]
    Isabelle Ray-Coquard
    Centre Leon Berard, 28, rue Laennec, 69008 Lyon
    Bull Cancer 94:S191-6. 2007
    ..This review article focuses on recent developments in the use of angiogenesis inhibitors for the treatment of breast, lung, and colorectal cancers...
  12. doi request reprint An increasing role for trabectedin in gynecological cancers: efficacy in uterine sarcomas
    Isabelle Ray-Coquard
    Centre Leon Berard, Lyon, France
    Int J Gynecol Cancer 21:S3-5. 2011
    ..These results are being confirmed in a current prospective phase II study in first-line uterine leiomyosarcoma combining trabectedin with doxorubicin...
  13. doi request reprint A risk model for severe anemia to select cancer patients for primary prophylaxis with epoetin alpha: a prospective randomized controlled trial of the ELYPSE study group
    I Ray-Coquard
    Department of Medical Oncology, Léon Bérard Comprehensive Cancer Center, University of Lyon, and EA 4128 SIS Individu Santé, Société, Lyon, France
    Ann Oncol 20:1105-12. 2009
    ....
  14. pmc Gemcitabine-oxaliplatin combination for ovarian cancer resistant to taxane-platinum treatment: a phase II study from the GINECO group
    I Ray-Coquard
    Centre Leon Berard, 28 rue Laennec, 69008 Lyon, France
    Br J Cancer 100:601-7. 2009
    ..6 and 11.4 months, respectively. The OXA-GE combination has high activity and acceptable toxicity in AOCEP patients. A comparison of the doublet OXA-GE with single-agent treatment is warranted...
  15. doi request reprint Management of rare ovarian cancers: the experience of the French website "Observatory for rare malignant tumours of the ovaries" by the GINECO group: interim analysis of the first 100 patients
    Isabelle Ray-Coquard
    Centre Leon Berard, SIS 4921, 28 rue Laennec, 69008 Lyon, France
    Gynecol Oncol 119:53-9. 2010
    ..We report the results of the first 100 patients with germ cell (GCT) and sex cord-stromal (SCT) tumours...
  16. doi request reprint [Rare ovarian tumours: therapeutic strategies in 2010, national website observatory for rare ovarian cancers and delineation of referent centers in France]
    I Ray-Coquard
    Centre Leon Berard, 28 rue Laennec, 69373 Lyon, France
    Bull Cancer 97:123-35. 2010
    ..The other new scientific data concern surgical procedures for sex cords tumors, evidence for presence of FOXL2 mutation in adult granulosa cell tumors, the use of paclitaxel plus carboplatin for sex cords tumors...
  17. doi request reprint [Incidence rate, epidemiology of sarcoma and molecular biology. Preliminary results from EMS study in the Rhône-Alpes region]
    F Ducimetière
    Centre Leon Berard, Equipe d évaluation des pratiques médicales, Lyon, France
    Bull Cancer 97:629-41. 2010
    ..Because sarcomas are relatively uncommon yet comprise a wide variety of different entities, second opinion was systematically performed for all included cases...
  18. ncbi request reprint Persistence of medical change at implementation of clinical guidelines on medical practice: a controlled study in a cancer network
    Isabelle Ray-Coquard
    Centre Leon Berard, 28, rue Laennec, 69008 Lyon, France
    J Clin Oncol 23:4414-23. 2005
    ..In the present study, we evaluated the persistence of conformity to guidelines through a new medical audit...
  19. ncbi request reprint Impact of a clinical guidelines program for breast and colon cancer in a French cancer center
    I Ray-Coquard
    Centre Leon Berard, Lyon, France
    JAMA 278:1591-5. 1997
    ....
  20. ncbi request reprint Vinorelbine and cisplatin (CIVIC regimen) for the treatment of metastatic breast carcinoma after failure of anthracycline- and/or paclitaxel-containing regimens
    I Ray-Coquard
    Centre Leon Berard, Lyon, France
    Cancer 82:134-40. 1998
    ..v.) infusion, and vinorelbine (VNB) was delivered at a dose of 6 mg i.v. bolus followed by VNB, 6 mg/m2/day, in continuous i.v. infusion (Days 1-5) every 21 days...
  21. pmc A controlled "before-after" study: impact of a clinical guidelines programme and regional cancer network organization on medical practice
    I Ray-Coquard
    Centre Leon Berard, 28, rue Laënnec 69008 Lyon, France
    Br J Cancer 86:313-21. 2002
    ..These results would suggest that introducing guidelines with specific implementation strategy might also increase the compliance rate with the guideline and "evidence-based medicine"...
  22. ncbi request reprint Epirubicin and paclitaxel (EPI-TAX regimen) for advanced ovarian cancer after failure of platinum-containing regimens
    Isabelle Ray-Coquard
    Centre Leon Berard, 28, rue Laennec, 69008, Lyon, France
    Gynecol Oncol 88:351-7. 2003
    ..We have assessed the feasibility and evaluated the tolerance of epirubicin (EPI) combined with paclitaxel (TAX) in heavily pretreated ovarian cancer patients...
  23. ncbi request reprint [Docetaxel and ovarian cancer]
    Isabelle Ray-Coquard
    Centre Leon Berard, 28, rue Laennec, 69008 Lyon
    Bull Cancer 91:159-65. 2004
    ..The positive clinical experiences with docetaxel-provide a strong basis for continued investigation of docetaxel-carboplatin-based chemotherapy as component of advanced ovarian cancer management...
  24. ncbi request reprint Evaluation of core needle biopsy as a substitute to open biopsy in the diagnosis of soft-tissue masses
    I Ray-Coquard
    Centre Leon Berard, 28 rue Laennec, Lyon 69008, France
    Eur J Cancer 39:2021-5. 2003
    ..CNB is accurate, not misleading for s-t-M diagnosis, avoids open biopsy complications, and allows one-surgery or neo-adjuvant chemotherapy planning when combined with appropriate imaging...
  25. ncbi request reprint Conformity to clinical practice guidelines, multidisciplinary management and outcome of treatment for soft tissue sarcomas
    I Ray-Coquard
    Centre Leon Berard, Lyon, France
    Ann Oncol 15:307-15. 2004
    ..The primary management of adult soft tissue sarcomas (STS) is characterized by heterogeneity across centers. Several studies suggest that it is improved when coordinated by specialized sarcoma centers...
  26. doi request reprint CD4 lymphopenia to identify end-of-life metastatic cancer patients
    Julien Peron
    Universite de Lyon, Lyon, France Université Lyon 1, Villeurbanne, France
    Eur J Cancer 49:1080-9. 2013
    ..Cancer patients with CD4 lymphopenia have an increased risk of severe toxicity after administration of cytotoxic chemotherapy. The impact of CD4 lymphopenia on long term overall survival (OS) of cancer patients was explored in this work...
  27. doi request reprint Chemotherapy for metastatic breast cancer. Comparison of clinical practice and cost of drugs in two cohorts of patients: 1994-1998 and 2003-2006
    Guillaume Galy
    Department of Pharmacy, Centre Leon Berard, Lyon, 69008, France
    Breast Cancer Res Treat 128:187-95. 2011
    ..56; P = 0.0002). New chemotherapeutic agents induced a significant cost increase over time. The limited size and heterogeneity of our cohort do not allow any conclusion concerning their impact on survival...
  28. ncbi request reprint Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group
    Jean Yves Blay
    Unité INSERM U590 Centre Léon Bérard and Université Claude Bernard Lyon I and Hopital Edouard Herriot, Lyon, France
    J Clin Oncol 25:1107-13. 2007
    ..Imatinib is the standard treatment of advanced GI stromal tumors (GISTs). It is not known whether imatinib may be stopped in patients in whom disease is controlled...
  29. doi request reprint Imatinib mesilate for the treatment of gastrointestinal stromal tumour
    Philippe A Cassier
    unité de jour d oncologie médicale multidisciplinaire, Pavillon E, Hopital Edouard Herriot, 5 Place d Arsonval, 69003, Lyon, France
    Expert Opin Pharmacother 9:1211-22. 2008
    ..Imatinib mesilate, which was approved in 2002 for the treatment of patients with advanced GIST, has dramatically changed the course of the disease...
  30. ncbi request reprint Emerging drugs for the treatment of soft tissue sarcomas
    Philippe A Cassier
    Unité de Jour Oncologie Médicale Multidisciplinaire, Hopital Edouard Herriot, Lyon, France
    Expert Opin Emerg Drugs 12:139-53. 2007
    ..This review summarises treatment strategies in the context of advanced disease and discusses new compounds being developed for patients with soft tissue sarcomas...
  31. doi request reprint [Clinical Practice guidelines for the use of erythropoiesis-stimulating agents (ESA: epoetin alfa, epoetin bêta, darbepoetin) in anaemic patients with cancer: 2007 update (summary report)]
    Isabelle Ray-Coquard
    Centre Leon Berard, Lyon
    Bull Cancer 95:433-41. 2008
    ..This article presents a short version of the Recommendations updated in 2007...
  32. doi request reprint A phase 2 trial of whole-brain radiotherapy combined with intravenous chemotherapy in patients with brain metastases from breast cancer
    Philippe A Cassier
    Multidisciplinary Medical Oncology Day Unit, Edouard Herriot Hospital, Lyon, France
    Cancer 113:2532-8. 2008
    ..A study was conducted to determine the efficacy, tolerability, and safety of concurrent cisplatin and vinorelbine chemotherapy and radiotherapy in patients with previously untreated brain metastases from breast cancer...
  33. doi request reprint Sorafenib in patients with progressive epithelioid hemangioendothelioma: a phase 2 study by the French Sarcoma Group (GSF/GETO)
    Christine Chevreau
    Department of Medical Oncology, Claudius Regaud Institute, Toulouse, France
    Cancer 119:2639-44. 2013
    ..There is no standard treatment for progressive epithelioid hemangioendothelioma (EHE). To investigate the significant vascularization of EHE, the activity/toxicity of sorafenib in patients with progressive EHE was explored...
  34. pmc Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas
    Isabelle Ray-Coquard
    Université de Lyon Centre Léon Bérard, Department of Medical Oncology and EA SIS 4128, Lyon, France
    Cancer Res 69:5383-91. 2009
    ..48; 95% CI, 1.03-2.1) along with IPI. Our findings show that lymphopenia is an independent prognostic factor for overall and progression-free survival in several cancers...
  35. ncbi request reprint Novel approaches to gastrointestinal stromal tumors resistant to imatinib and sunitinib
    Philippe A Cassier
    Conticanet Network of Excellence LSH 060188, Département de Médicine, Centre Leon Berard, 28 rue Laennec, 69008 Lyon, France
    Curr Gastroenterol Rep 10:555-61. 2008
    ..This article reviews the current knowledge regarding IM and SU resistance in GIST, as well as the available options for the management of GIST resistant to IM and SU...
  36. ncbi request reprint [Cyclooxygenase 2 and breast cancer. From biological concepts to therapeutic trials]
    Jean Paul Guastalla
    Centre Leon Berard, 28, rue Laennec, 69008 Lyon
    Bull Cancer 91:S99-108. 2004
    ..Clinical trials are planed with the anti Cox2 celecoxib for breast cancer prevention, in adjuvant setting, in metastatic situation combined with exemestane or antitubulin drugs or in neoadjuvant therapy...
  37. doi request reprint Insulin-like growth factor type 1 receptor (IGF-1R) exclusive nuclear staining: a predictive biomarker for IGF-1R monoclonal antibody (Ab) therapy in sarcomas
    Irène Asmane
    CHU Strasbourg, 1, Avenue Moliere, 67000 Strasbourg, France
    Eur J Cancer 48:3027-35. 2012
    ..A biomarker identifying those patients beforehand would be useful to select patients for the development of these agents...
  38. doi request reprint Multidisciplinarity and medical decision, impact for patients with cancer: sociological assessment of two tumour committees' organization
    Patrick Castel
    Centre Leon Berard, Lyon, France
    Bull Cancer 99:E34-42. 2012
    ..In the present study, we evaluated the organization of two multidisciplinary committees, one for breast cancer and one for sarcoma, in a French Comprehensive Cancer Centre...
  39. doi request reprint Bevacizumab and paclitaxel for breast cancer patients with central nervous system metastases: a case series
    Sana Intidhar Labidi
    Department of Medical Oncology, Centre Leon Berard, Laennec, France
    Clin Breast Cancer 9:118-21. 2009
    ....
  40. ncbi request reprint [Recommendations for the management of GIST patients]
    Jean Yves Blay
    Unité Inserm 590, Centre Leon Berard, 69008 Lyon
    Bull Cancer 92:907-18. 2005
    ..A national consensus meeting was therefore organized in order to identify the optimal management procedures for patients with GIST in localized and advanced stages...
  41. doi request reprint 2007 Standards, Options, and Recommendations: use of erythropoiesis-stimulating agents (ESA: epoetin alfa, epoetin beta, and darbepoetin) for the management of anemia in children with cancer
    Perrine Marec-Berard
    Department of Pediatrics, Hemato Oncologic Pediatric Institute, Lyon, France
    Pediatr Blood Cancer 53:7-12. 2009
    ..However, treatment decision must be made on a case-by-case basis and, when treatment is considered, the intravenous route must be preferred. The full French document is available at www.sor-cancer.fr...
  42. ncbi request reprint [Anemia and chemotherapy]
    Isabelle Ray-Coquard
    Centre Leon Berard, 28, rue Laennec, 69008 Lyon
    Bull Cancer 90:S133-43. 2003
    ..In addition, anemia could relieve of specific treatment such as blood transfusion or preventive treatment with recombinant erythropoietin...
  43. pmc Long-term outcome and effect of maintenance therapy in patients with advanced sarcoma treated with trabectedin: an analysis of 181 patients of the French ATU compassionate use program
    Jean Yves Blay
    Centre Leon Berard, Lyon, France
    BMC Cancer 13:64. 2013
    ..The long term outcome of advanced sarcoma patients treated with trabectedin outside of clinical trials and the utility of maintenance treatment has not been reported...
  44. ncbi request reprint [Gastro-intestinal stromal tumors: news and comments]
    Isabelle Ray-Coquard
    Clinique Mutualiste Eugène André, Lyon, et Centre Léon Bérard, 28, rue Laennec, 69008 Lyon
    Bull Cancer 90:69-76. 2003
    ..Numerous question regarding the integration of this treatment with surgery and the long term outcome of these patients still remain to be answered however...
  45. ncbi request reprint [Neoadjuvant chemotherapy in sarcoma]
    Jean Yves Blay
    Hôpital Edouard Herriot et Unité Inserm U590, Centre Leon Berard, 28, rue Laennec, 69008 Lyon
    Bull Cancer 93:1093-8. 2006
    ..In elderly and/or frail patients, conversely, single agent doxorubicin may be the preferred option...
  46. pmc Phase I combination study of trabectedin and doxorubicin in patients with soft-tissue sarcoma
    Jean Yves Blay
    CONTICANET and UJOMM Hôpital Edouard Herrot, Centre Leon Berard, Lyon, France
    Clin Cancer Res 14:6656-62. 2008
    ..Blood was collected during cycle 1 for pharmacokinetic analyses. Adverse events, tumor response, and survival were assessed...
  47. doi request reprint A phase II study of gefitinib for patients with advanced HER-1 expressing synovial sarcoma refractory to doxorubicin-containing regimens
    Isabelle Ray-Coquard
    Centre Léon Bérard and UJOMM H E Herriot, Lyon, France
    Oncologist 13:467-73. 2008
    ..Based on a report showing a specific overexpression of HER-1 in SyS, we investigated an HER-1 inhibitor, gefitinib, in refractory SyS...
  48. doi request reprint Therapeutic pipeline for soft-tissue sarcoma
    Philippe A Cassier
    Departement de Medecine, Centre Leon Berard, 69008 Lyon, France
    Expert Opin Pharmacother 12:2479-91. 2011
    ..After the initial success of imatinib in gastrointestinal stromal tumors, several other compounds have shown promising activity in some but not all subgroups of sarcoma...
  49. pmc Outcome of patients with advanced solitary fibrous tumors: the Centre Léon Bérard experience
    Alice Levard
    Department of Medical Oncology, Centre Leon Berard, 28 rue Laennec, 69008, Lyon, France
    BMC Cancer 13:109. 2013
    ..Data on the management of patients with advanced SFT is scarce: chemotherapy has been described as ineffective, while recent data suggests that anti-angiogenic therapies may be more efficient...
  50. doi request reprint [Antihormonal therapy in breast cancer and mTOR inhibitors]
    Pierre Etienne Heudel
    Centre Leon Berard, Oncologie Médicale, Lyon, France
    Bull Cancer 98:1431-7. 2011
    ....
  51. pmc Prognostic value of the expression of C-Chemokine Receptor 6 and 7 and their ligands in non-metastatic breast cancer
    Philippe A Cassier
    Department of Medecine, Centre Leon Berard, Lyon, France
    BMC Cancer 11:213. 2011
    ..Chemokines CCL19, CCL20 and CCL21 and their receptors CCR6 and CCR7, were assessed as potential biomarkers of metastatic dissemination in primary breast cancer...
  52. pmc Validation of prognostic scores for survival in cancer patients beyond first-line therapy
    Olivier Tredan
    Universite de Lyon, Centre Leon Berard, Department of Medical Oncology, 28 rue Laennec, 69008 Lyon, France
    BMC Cancer 11:95. 2011
    ..We aimed to validate prognostic scores for survival in patients undergoing chemotherapy for advanced or metastatic cancer after first-line treatment...
  53. doi request reprint Efficacy of trabectedin for advanced sarcomas in clinical trials versus compassionate use programs: analysis of 92 patients treated in a single institution
    Jerome Fayette
    Department of Medicine, Unite INSERM, Centre Leon Berard, Lyon, France
    Anticancer Drugs 21:113-9. 2010
    ..The safety and tolerability of trabectedin shown in clinical trials is confirmed for patients in real-life situation treated in compassionate use programs, but its benefit is higher for patients with performance status 0-1...
  54. ncbi request reprint [Angiogenesis and breast cancer]
    Thomas Bachelot
    Centre Leon Berard, Departement de Medecine, 28, rue Laennec, 69373 Lyon Cedex 08
    Bull Cancer 94:S203-10. 2007
    ..This is a review of the major biological and clinical data available on the critical role of angiogenesis in breast cancer. We will also review the different clinical studies reported to date in this area...
  55. pmc Can treatment with Cocculine improve the control of chemotherapy-induced emesis in early breast cancer patients? A randomized, multi-centered, double-blind, placebo-controlled Phase III trial
    David Perol
    Centre Leon Berard, 28 rue Laennec, Lyon Cedex 08, 69373, France
    BMC Cancer 12:603. 2012
    ....
  56. doi request reprint Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study
    Thomas Bachelot
    Département de Cancérologie Médicale et Unité INSERM U590, Centre Leon Berard, 28 rue Laennec, 69373 Lyon Cedex 08, France
    J Clin Oncol 30:2718-24. 2012
    ..This analysis evaluated efficacy and safety of everolimus in combination with tamoxifen in patients with mBC resistant to aromatase inhibitors (AIs)...
  57. doi request reprint First-line endocrine therapy alone could be a reasonable treatment option for hormone-positive, HER2-positive metastatic breast cancer
    Julien Peron
    Centre Leon Berard, Department of Medical Oncology, 28, rue Laennec, 69008 Lyon, France
    Bull Cancer 99:E18-25. 2012
    ..Previously validated clinical practice guidelines recommending the use of endocrine therapy alone in first line might be changed...
  58. ncbi request reprint CD4 lymphopenia as a risk factor for febrile neutropenia and early death after cytotoxic chemotherapy in adult patients with cancer
    Christophe Borg
    INSERM U590, Centre Leon Berard, Lyon, France
    Cancer 101:2675-80. 2004
    ..Lymphopenia is frequently observed in patients with cancer and correlates with the risk of febrile neutropenia and early death after chemotherapy. The phenotype of the depleted lymphocyte populations was investigated in the current study...
  59. pmc Incidence of sarcoma histotypes and molecular subtypes in a prospective epidemiological study with central pathology review and molecular testing
    Françoise Ducimetière
    Universite de Lyon, Cancer Centre Léon Bérard, EA 4129, Lyon, France
    PLoS ONE 6:e20294. 2011
    ..The objective of the present population-based study was to determine this incidence in a European region (Rhone-Alpes) of six million inhabitants, based on a central pathological review of the cases...
  60. doi request reprint Is there a role for discontinuing imatinib in patients with advanced gastrointestinal stromal tumour?
    Jean Yves Blay
    Département de Médecine and Unité INSERM U590, Centre Leon Berard, Lyon, France
    Curr Opin Oncol 21:360-6. 2009
    ..In this setting, the optimal duration of treatment is not known, and it is generally considered that treatment should be given until progression or intolerance...
  61. doi request reprint [Targeted therapy of sarcomas]
    Philippe A Cassier
    Hopital Edouard Herriot, Service d Oncologie Medicale, Lyon, France
    Bull Cancer 95:963-74. 2008
    ..Together with the current development of numerous targeted therapies, these recent progress are the basis of tomorrow's personalised medicine for patients with soft tissue sarcoma...
  62. pmc Pazopanib for the treatment of soft-tissue sarcoma
    Pierre Heudel
    Department of Medical Oncology, Leon Berard Center, Lyon, France
    Clin Pharmacol 4:65-70. 2012
    ..In comparison with sunitinib or sorafenib, pazopanib has a similar toxicity profile and is generally well tolerated. This review details the development of this new therapeutic class in the treatment of metastatic soft-tissue sarcomas...
  63. pmc Clinicians' adherence versus non adherence to practice guidelines in the management of patients with sarcoma: a cost-effectiveness assessment in two European regions
    Lionel Perrier
    University of Lyon, F 69007 Lyon, France
    BMC Health Serv Res 12:82. 2012
    ....
  64. doi request reprint Management of anemia in advanced breast and lung cancer patients in daily practice: results of a French survey
    Isabelle Ray-Coquard
    Departement d Oncologie Medicale, Centre Leon Berard, Lyon, France
    Adv Ther 29:124-33. 2012
    ....
  65. ncbi request reprint Lymphopenia: a new independent prognostic factor for survival in patients treated with whole brain radiotherapy for brain metastases from breast carcinoma
    Line Claude
    Department of Radiation Oncology, Hopital Edouard Herriot, Lyon, France
    Radiother Oncol 76:334-9. 2005
    ..To determine overall survival (OS) and independent prognostic factors in patients with brain metastases (BM) from breast cancer treated by whole brain radiotherapy (WBR)...
  66. doi request reprint ERCC5/XPG, ERCC1, and BRCA1 gene status and clinical benefit of trabectedin in patients with soft tissue sarcoma
    Antoine Italiano
    Department of Medical Oncology, Institut Bergonie, Bordeaux, France
    Cancer 117:3445-56. 2011
    ....
  67. doi request reprint Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study
    Isabelle Ray-Coquard
    Centre Leon Berard, Lyon, France EAM 4128 Santé Individu Société, Universite Claude Bernard Lyon I, Lyon, France
    Lancet Oncol 13:1133-40. 2012
    ..We report a proof-of-mechanism study of RG7112, a small-molecule MDM2 antagonist, in patients with chemotherapy-naive primary or relapsed well-differentiated or dedifferentiated MDM2-amplified liposarcoma who were eligible for resection...
  68. pmc Recombinant erythropoietin for the anaemia of patients with advanced Gastrointestinal Stromal Tumours (GIST) receiving imatinib: an active agent only in non progressive patients
    Florence Duffaud
    Centre Leon Berard, Department of Medecine, French Sarcoma Group GSF GETO, European Organisation for Research and Treatment of Cancer EORTC, University Claude Bernard Lyon I, Lyon, France
    Clin Sarcoma Res 2:11. 2012
    ..ABSTRACT: Recombinant erythropoietin for the anaemia of patients with advanced Gastrointestinal Stromal Tumours (GIST) receiving imatinib : an active agent only in non progressive patients...
  69. pmc Epidemiological evaluation of concordance between initial diagnosis and central pathology review in a comprehensive and prospective series of sarcoma patients in the Rhone-Alpes region
    Antoine Lurkin
    Centre Leon Berard, Lyon, France
    BMC Cancer 10:150. 2010
    ..We prospectively assessed the medical management of all patients diagnosed with sarcoma in a European region over a one-year period to identify the quantity of first diagnosis compared to central expert review (CER)...
  70. ncbi request reprint [Adjuvant therapy for breast cancer patients: treatment decision tree from a French cancer network]
    Thomas Bachelot
    Centre Leon Berard, 28, rue Laennec, 69373 Lyon Cedex 08, France
    Bull Cancer 89:897-903. 2002
    ..However, due to the subjectivity of risk/benefit estimations, patients themselves should become more involved in the decision-making process...
  71. doi request reprint Quantitative and functional alterations of plasmacytoid dendritic cells contribute to immune tolerance in ovarian cancer
    Sana Intidhar Labidi-Galy
    Departments of Medical Oncology, Centre de Recherche en Cancérologie de Lyon, Centre Leon Berard, Lyon, France
    Cancer Res 71:5423-34. 2011
    ..Taken together, our findings indicate that both local and systemic dysfunction of pDC play a critical role in the progression of ovarian cancer via induction of immune tolerance...
  72. ncbi request reprint [Adjuvant therapies: the example of breast cancer]
    Thomas Bachelot
    Centre Leon Berard, 69008 Lyon
    Rev Prat 58:817-9. 2008
    ..The development of national and regional therapeutic guidelines markedly diminished the arbitrary aspect of the decision. Developing tools which could help implying the patient in this therapeutic decision is a priority...
  73. ncbi request reprint [Cyclooxygenase 2 and breast cancer. From biological concepts to clinical trials]
    Jean Paul Guastalla
    Centre Leon Berard, 28, rue Laennec, 69008 Lyon
    Bull Cancer 91:S99-108. 2004
    ..Clinical trials are planed with the anti Cox2 celecoxib for breast cancer prevention, in adjuvant setting, in metastatic situation combined with exemestane or antitubulin drugs or in neoadjuvant therapy...
  74. ncbi request reprint Risk model predictive of severe anemia requiring RBC transfusion after chemotherapy in pediatric solid tumor patients
    Perrine Marec-Berard
    Pediatric Oncology Unit, INSERM U590, the Statistics department, and Centre Léon Bérard, Lyon Cedex, France
    J Clin Oncol 21:4235-8. 2003
    ..This model is tested on a pediatric population...
  75. ncbi request reprint [Organization and impact of the multidisciplinary committee in oncology]
    Patrick Castel
    GRESAC, LASS CNRS FRE2747 Centre Léon Bérard, Lyon
    Bull Cancer 91:799-804. 2004
    ..Indeed, this case study shows that the quality of decisions does not only rely on the collective deliberation, but also on the individual and specific competencies of some members of the committee that other members admit...
  76. pmc Sorafenib for patients with advanced angiosarcoma: a phase II Trial from the French Sarcoma Group (GSF/GETO)
    Isabelle Ray-Coquard
    Department of Medical Oncology, Centre Leon Berard, Lyon, France
    Oncologist 17:260-6. 2012
    ..We investigated the antitumor activity of sorafenib in patients with metastatic or advanced angiosarcomas in a phase II trial...
  77. doi request reprint [PAIR-gynaecology: multi/interdisciplinary for gynecologic cancer research. Problems needed to be resolved]
    Isabelle Ray-Coquard
    Université Lyon I, Centre Leon Berard, France
    Bull Cancer 99:479-98. 2012
    ....
  78. pmc Factors of interrupting chemotherapy in patients with Advanced Non-Small-Cell Lung Cancer
    Rhizlane Belbaraka
    Department of Medical Oncology, Centre Leon Berard, 28 rue Laennec, Lyon 69008, France
    BMC Res Notes 3:164. 2010
    ..In this prospective study, which included 45 patients, we identified clinical and biological variables as outcome predictors in metastatic Non-Small Cell lung cancer after first line chemotherapy were identified...
  79. ncbi request reprint [Targeted treatment of cancers with imatinib mesylate (STI571, Gleevec): results of Asco 2002]
    Isabelle Ray-Coquard
    INSERM U 453, Centre Leon Berard, 28, rue Laennec, 69008 Lyon, France
    Bull Cancer 89:567-9. 2002
  80. ncbi request reprint Low serum albumin levels and liver metastasis are powerful prognostic markers for survival in patients with carcinomas of unknown primary site
    Pascal Seve
    Department of Internal Medicine, Hotel Dieu, Hospices Civils de Lyon, Lyon, France
    Cancer 107:2698-705. 2006
    ..The authors investigated how lymphopenia and low serum albumin levels correlate with the prognosis of patients with carcinoma of unknown primary (CUP)...
  81. ncbi request reprint Phase I study of high-dose topotecan with haematopoietic stem cell support in the treatment of ovarian carcinomas: the ITOV 01 protocol
    J P Lotz
    Department of Medical Oncology, Hopital Tenon, Assistance Publique Hopitaux de Paris, Universite Pierre et Marie Curie, Paris, France
    Bone Marrow Transplant 37:669-75. 2006
    ..Two episodes of grade IV diarrhoea were observed at level 9.5 mg/m2/day. Pharmacokinetic data were linear within the dose range of 4-9.0 mg/m2/day. The MTD was reached at 9 mg/m2/day x 5 days...
  82. ncbi request reprint Cisplatin-based chemotherapy regimen (DECAV) for uterine sarcomas
    P Pautier
    Department of Medical Oncology, Institut Gustave Roussy, Villejuif, France
    Int J Gynecol Cancer 12:749-54. 2002
    ..Median overall survival was 14 month overall, 45 months for Group 1 and 13 months for Group 2. We conclude that the DECAV regimen is clearly active in uterine sarcomas but is too toxic to be recommended routinely...
  83. ncbi request reprint Adjuvant chemotherapy with cisplatin, ifosfamide, and doxorubicin followed by radiotherapy in localized uterine sarcomas: results of a case-control study with radiotherapy alone
    P Pautier
    Department of Medical Oncology, Institut Gustave Roussy, Villejuif Cedex, France
    Int J Gynecol Cancer 14:1112-7. 2004
    ..Compared to a case-control study of adjuvant radiotherapy alone, results were not decreased by the addition of a toxic chemotherapy...
  84. ncbi request reprint Results of a prospective dose-intensive regimen in 27 patients with small cell carcinoma of the ovary of the hypercalcemic type
    P Pautier
    Department of Medical Oncology, Institut Gustave Roussy, Villejuif, France
    Ann Oncol 18:1985-9. 2007
    ..The evaluation of first-line intensive combination therapy in small cell carcinoma of the ovary (SCCO)...
  85. ncbi request reprint Pilot study of the paclitaxel, oxaliplatin, and cisplatin combination in patients with advanced/recurrent ovarian cancer
    S Delaloge
    Department of Medical Oncology, H pital Paul Brousse, Villejuif, France
    Am J Clin Oncol 23:569-74. 2000
    ..This active combination shows acceptable hematologic toxicity, and reversible cumulative neurosensory toxicity. Further clinical exploration of the present combination appears warranted...
  86. ncbi request reprint An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-OV28) in assessing the quality of life of patients with ovarian cancer
    E Greimel
    Department of Obstetrics and Gynecology, University of Graz, Auenbruggerplatz 14, A 8036 Graz, Austria
    Eur J Cancer 39:1402-8. 2003
    ..All hypothesised scales exhibited good psychometric properties. These results support the clinical and psychometric validity of the EORTC QLQ-OV28 module as a supplement to the EORTC QLQ-C30...
  87. pmc Lack of relationship between EGFR-1 immunohistochemical expression and prognosis in a multicentre clinical trial of 93 patients with advanced primary ovarian epithelial cancer (GINECO group)
    C Elie
    INSERM U472, Faculte de Medecine, Paris Sud, France
    Br J Cancer 91:470-5. 2004
    ..The potential effect of EGFR-1 and HER-2 co-expression on targeted therapy against EGFR-1 and/or HER-2 molecules has to be further analysed...